Charlene McDanal

Duke University — United States

Medicine · Health Sciences

32h-index11.8kcitations45works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

SARS-CoV-2 and COVID-19 Research(23), HIV Research and Treatment(20), COVID-19 Clinical Research Studies(13), Animal Virus Infections Studies(11), SARS-CoV-2 detection and testing(10)

Publications45 total

Mapping SARS-CoV-2 antigenic relationships and serological responses
Science·2023· 129 citedOpen Access
Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial
Viruses·2023· 15 citedOpen Access
Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial
Science Translational Medicine·2023· 45 citedOpen Access
Mapping SARS-CoV-2 antigenic relationships and serological responses
2022· 67 citedOpen Access
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
Science·2022· 1.2k citedOpen Access
Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization
2021· 129 citedOpen Access
Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation
Scientific Reports·2021· 74 citedOpen Access
COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models
Nature Communications·2021· 54 citedOpen Access
Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation
2021· 2 citedOpen Access
Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation
2021· 10 citedOpen Access
Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial
2021· 137 citedOpen Access
Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates
Science·2021· 322 citedOpen Access
In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies
UNC Libraries·2021· 19 citedOpen Access
In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies
Cell·2021· 325 citedOpen Access
Immune Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection in Nonhuman Primates
2021· 51 citedOpen Access
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines
Cell Host & Microbe·2021· 391 citedOpen Access
COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models
2021· 20 citedOpen Access
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines
2021· 78 citedOpen Access
The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates
2021· 73 citedOpen Access
SARS-CoV-2 Variant B.1.1.7 is Susceptible to Neutralizing Antibodies Elicited by Ancestral Spike Vaccines
SSRN Electronic Journal·2021· 3 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

David C. Montefiori(23), Rolando Pajón(13), Thomas J. Matthews(10), Barton F. Haynes(10), Amanda Eaton(8), Bette Korber(7), Haili Tang(7), Peter B. Gilbert(7), Marcella Sarzotti‐Kelsoe(7), Lawrence Corey(7), Lindsay N. Carpp(7), A J Langlois(7), Mark G. Lewis(7), John R. Mascola(7), Nicolas Hengartner(6), Adrian B. McDermott(6), Britta Flach(6), Xiaoying Shen(6), Sarah O’Connell(5), Robert J. Edwards(5)